【摘要】 腱鞘巨细胞瘤（TGCT）是一种罕见的间叶源性肿瘤，好发于关节、腱鞘及滑囊，包括结节型TGCT(N-TGCT)和弥漫型TGCT(D-TGCT)。与N-TGCT相比，D-TGCT的局部侵袭性更强。TGCT的传统治疗方法是手术切除，但术后常出现局部复发，反复多次复发会影响患者生活质量，严重者甚至危及患者生命。随着骨与软组织肿瘤治疗理念的更新、技术的进步、多学科综合治疗的日益完善，尤其是集落刺激因子1受体（CSF1R）抑制剂的问世和临床应用，TGCT患者的预后有望得到明显改善。中华医学会骨科学分会骨肿瘤学组联合中国临床肿瘤学会肉瘤专家委员会组织相关专家制定《中国腱鞘巨细胞瘤临床诊疗专家共识》，规范化TGCT的临床诊疗实践，以改善TGCT患者的预后。更多还原

【Abstract】 Tenosynovial giant cell tumor(TGCT) is a rare mesenchymal tumor that commonly arises in joints, tendon sheaths, and bursae. It comprises the nodular type(N-TGCT) and the diffuse type(D-TGCT). Compared with N-TGCT, D-TGCT exhibits stronger local aggressiveness. Surgical resection is the traditional treatment for TGCT; however, postoperative local recurrence is common. Repeated recurrences can affect patients’ quality of life and, in severe cases, even pose a life-threatening risk. With the evolution of treatment concepts, advances in technology, and the growing adoption of multidisciplinary comprehensive treatment for bone and soft tissue tumors, particularly the introduction and clinical application of colony-stimulating factor 1 receptor(CSF1R) inhibitors, the prognosis of TGCT patients is anticipated to markedly improve in light of these developments. The Bone Oncology Group of the Orthopaedic Branch of the Chinese Medical Association and the Sarcoma Expert Committee of the Chinese Society of Clinical Oncology have jointly formulated the Chinese Expert Consensus on the Clinical Diagnosis and Treatment of Tenosynovial Giant Cell Tumor, aiming to standardize clinical practices and improve patient outcomes.更多还原